U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06915870) titled 'Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment' on March 27.
Brief Summary: Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily. All participants were followed-up in OPD after 12 weeks for assessment of ejection fraction.
Study Start Date: July 12, 2024
Study Type: INTERVENTIONAL
Condition:
Diabetes Mellitus
Heart Failure
Intervention:
DRUG: Dapagliflozin 10 mg daily
Dapagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and AR...